NUZ Neurizon Therapeutics Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Returns
| 1 day | 6.7% |
| 1 week | 3.9% |
| 1 month | 45.5% |
| 3 months | 9.6% |
| 6 months | -2.4% |
| 1 year | -48.4% |
| 3 years | 0.0% |
Risk
| Volatility (1y ann.) | 77.8% |
| Beta vs ASX 200 | 0.62 |
| Sharpe (1y) | -0.52 |
| VaR 95% (1-day) | -6.0% |
| Max drawdown (1y) | -63.3% |
| Off 1-year high | -46.7% |
Technicals
| RSI(14) | 63 |
| vs 50DMA | 20.0% |
| vs 200DMA | 5.5% |
| Trend | Death cross |
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.02
- Free cash flow—
- Net debt—